Hypercholesterolemia Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Hais

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypercholesterolemia pipeline constitutes 25+ key companies continuously working towards developing 30+ Hypercholesterolemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hypercholesterolemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypercholesterolemia Market.

The Hypercholesterolemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hypercholesterolemia Pipeline Report: https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hypercholesterolemia treatment therapies with a considerable amount of success over the years.
• Hypercholesterolemia companies working in the treatment market are EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Haisco Pharmaceutical Group Co., Ltd., Akeso Biopharma, Addpharma Inc., Jiangsu HengRui Medicine Co., Ltd., and others, are developing therapies for the Hypercholesterolemia treatment
• Emerging Hypercholesterolemia therapies in the different phases of clinical trials are- EPIC-221, AMTX 100, Research programme: epigenetic editors, VERVE-101, VXX-401, ARO-ANG 3, MK-0616, HSK31679, Ebronucimab, AD-221, SHR-1209, and others are expected to have a significant impact on the Hypercholesterolemia market in the coming years.
• In April 2025, Verve Therapeutics, a clinical-stage biotech developing innovative genetic medicines for cardiovascular disease, announced promising initial results from its Heart-2 Phase 1b trial of VERVE-102. This trial focuses on patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), groups needing substantial and lasting reductions in low-density lipoprotein cholesterol (LDL-C). Among 14 participants treated across three dosing levels, VERVE-102 showed good tolerability, with no treatment-related serious adverse events (SAEs) or significant lab abnormalities. A single infusion of VERVE-102 produced dose-dependent reductions in blood PCSK9 protein and LDL-C, with an average LDL-C drop of 53% and a maximum reduction of 69% in the 0.6 mg/kg group.
• In January 2025, LIB Therapeutics Inc. (LIB), a private late-stage biopharmaceutical company developing Lerodalcibep, a next-generation PCSK9 inhibitor, announced that the Phase 3 LIBerate-HoFH study has been published in Lancet Diabetes & Endocrinology. This study assessed Lerodalcibep in a globally diverse population with homozygous familial hypercholesterolemia (HoFH).
• In November 2024, Esperion (NASDAQ: ESPR) announced that Otsuka Pharmaceutical Co., Ltd. has filed a New Drug Application (NDA) with Japan's Ministry of Health, Labour and Welfare seeking approval to manufacture and market bempedoic acid for treating hypercholesterolemia and familial hypercholesterolemia in Japan.
• In April 2024, Repatha (evolocumab) is a human monoclonal antibody that targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), effectively reducing cholesterol levels. It is approved to lower the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease (CVD). Furthermore, Repatha is used to treat primary hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH), helping to decrease low-density lipoprotein cholesterol (LDL-C) when diet and other therapies are not enough.

Hypercholesterolemia Overview
Hypercholesterolemia is a condition characterized by high levels of cholesterol in the blood. This can lead to the buildup of fatty deposits in the arteries, increasing the risk of heart disease, stroke, and other cardiovascular problems. It is often caused by genetic factors, an unhealthy diet, lack of exercise, or other underlying health conditions.

Get a Free Sample PDF Report to know more about Hypercholesterolemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hypercholesterolemia Drugs Under Different Phases of Clinical Development Include:
• EPIC-221: EPIC BIO
• AMTX 100: Amytrx Therapeutics
• Research programme: epigenetic editors: Chroma Medicine
• VERVE-101: Verve Therapeutics, Inc
• VXX-401: Vaxxinity, Inc
• ARO-ANG 3: Arrowhead Pharmaceuticals
• MK-0616: Merck Sharp & Dohme LLC
• HSK31679: Haisco Pharmaceutical Group Co., Ltd.
• Ebronucimab: Akeso Biopharma
• AD-221: Addpharma Inc.
• SHR-1209: Jiangsu HengRui Medicine Co., Ltd.

Hypercholesterolemia Pipeline Therapeutics Assessment
• Hypercholesterolemia Assessment by Product Type
• Hypercholesterolemia By Stage and Product Type
• Hypercholesterolemia Assessment by Route of Administration
• Hypercholesterolemia By Stage and Route of Administration
• Hypercholesterolemia Assessment by Molecule Type
• Hypercholesterolemia by Stage and Molecule Type

DelveInsight's Hypercholesterolemia Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hypercholesterolemia product details are provided in the report. Download the Hypercholesterolemia pipeline report to learn more about the emerging Hypercholesterolemia therapies at:
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hypercholesterolemia Therapeutics Market include:
Key companies developing therapies for Hypercholesterolemia are - Regeneron Pharmaceuticals Inc, Verve Therapeutics Inc, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Huons Co Ltd, LipimetiX Development Inc, Novartis AG, Nyrada Inc, Addpharma Inc, and others.

Hypercholesterolemia Pipeline Analysis:
The Hypercholesterolemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypercholesterolemia Treatment.
• Hypercholesterolemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypercholesterolemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypercholesterolemia drugs and therapies-
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypercholesterolemia Pipeline Market Drivers
• Increase in prevalence of Hypercholesterolemia, rising number of clinical studies for the treatment of Hypercholesterolemia are some of the important factors that are fueling the Hypercholesterolemia Market.

Hypercholesterolemia Pipeline Market Barriers
• However, high cost associated with the treatment, side effects associated with the disease and other factors are creating obstacles in the Hypercholesterolemia Market growth.

Scope of Hypercholesterolemia Pipeline Drug Insight
• Coverage: Global
• Key Hypercholesterolemia Companies: EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Haisco Pharmaceutical Group Co., Ltd., Akeso Biopharma, Addpharma Inc., Jiangsu HengRui Medicine Co., Ltd., and others
• Key Hypercholesterolemia Therapies: EPIC-221, AMTX 100, Research programme: epigenetic editors, VERVE-101, VXX-401, ARO-ANG 3, MK-0616, HSK31679, Ebronucimab, AD-221, SHR-1209, and others
• Hypercholesterolemia Therapeutic Assessment: Hypercholesterolemia current marketed and Hypercholesterolemia emerging therapies
• Hypercholesterolemia Market Dynamics: Hypercholesterolemia market drivers and Hypercholesterolemia market barriers

Request for Sample PDF Report for Hypercholesterolemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hypercholesterolemia Report Introduction
2. Hypercholesterolemia Executive Summary
3. Hypercholesterolemia Overview
4. Hypercholesterolemia- Analytical Perspective In-depth Commercial Assessment
5. Hypercholesterolemia Pipeline Therapeutics
6. Hypercholesterolemia Late Stage Products (Phase II/III)
7. Hypercholesterolemia Mid Stage Products (Phase II)
8. Hypercholesterolemia Early Stage Products (Phase I)
9. Hypercholesterolemia Preclinical Stage Products
10. Hypercholesterolemia Therapeutics Assessment
11. Hypercholesterolemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypercholesterolemia Key Companies
14. Hypercholesterolemia Key Products
15. Hypercholesterolemia Unmet Needs
16 . Hypercholesterolemia Market Drivers and Barriers
17. Hypercholesterolemia Future Perspectives and Conclusion
18. Hypercholesterolemia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Hypercholesterolemia Market https://www.delveinsight.com/report-store/hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.